What are the primary performance benefits of boldenone undecylenate compared to testosterone?

Boldenone undecylenate offers three core advantages over testosterone at equivalent weekly doses: approximately half the aromatisation rate (reducing estrogenic side effects), direct erythropoietic stimulation raising red blood cell count and aerobic capacity, and sustained nitrogen retention for lean-mass accrual. These properties make it a preferred choice for athletes who want anabolic output with lower oestrogen-driven fluid accumulation and a cleaner visual outcome.

What unique characteristics distinguish boldenone undecylenate from other injectable anabolics?

Boldenone undecylenate is uniquely positioned by its dual-axis activity: androgen-receptor-mediated muscle protein synthesis combined with renal erythropoietin stimulation for haematocrit elevation. This combination is not replicated by DHT derivatives, which lack meaningful erythropoietic activity, or by nandrolone, which carries greater progestin-receptor affinity. Its 1,4-diene A-ring structure also prevents 5α-reduction to a more androgenic metabolite, limiting scalp and skin androgenic burden.

Why do experienced bodybuilders consistently choose boldenone undecylenate as part of their anabolic stack?

Experienced athletes select boldenone undecylenate because it occupies a pharmacological niche that testosterone and nandrolone do not fully cover: low estrogenic conversion, measurable haematopoietic benefit, and long plasma stability from the undecylenate ester. These properties allow it to serve as a lean-mass anchor in multi-compound protocols without duplicating the role of the testosterone base, adding a distinct physiological contribution rather than redundant androgenic load.

How should Swiss Pharma Boldenone 250mg/ml be drawn and measured using an insulin syringe for lower weekly doses?

For doses below 250mg, a 1ml insulin syringe graduated in 0.01ml increments allows accurate draws: at 250mg/ml, each 0.01ml graduation corresponds to 2.5mg, giving users 2.5mg dose resolution per mark. A 100mg dose requires a 0.40ml draw and a 150mg dose requires a 0.60ml draw — both achievable without fractional estimation error on a standard insulin syringe.

What are the storage requirements for Swiss Pharma Boldenone 250mg/ml after the vial has been opened?

Once punctured, the 10ml vial should be stored at room temperature between 15°C and 25°C, away from direct light and moisture. Refrigeration is not required but is acceptable; however, cold oil-based solutions should be warmed to room temperature before injection to reduce injection-site discomfort. The benzyl alcohol preservative system in oil-based injectables maintains antimicrobial protection across multiple draws, but the vial should be discarded if visible particulate matter or discolouration develops. (2) angle_used

Original Product

Swiss Pharma

Boldenone 250mg/ml 10ml Vial by Swiss Pharma

Name: Boldenone 250mg/ml 10ml Vial by Swiss Pharma
Brand: Swiss Pharma
SKU: INJ-BOLD-SWI-250-024
Price: 50.00 EUR
Availability: InStock

Swiss Pharma Boldenone 250mg/ml is a single-ingredient injectable anabolic formulated as boldenone undecylenate at 250mg per millilitre in a sealed 10ml multi-dose vial, purpose-built to deliver a clearly defined set of performance advantages: sustained lean-mass accrual, enhanced nitrogen retention, and erythropoietic support without excessive estrogenic activity. The 250mg/ml concentration occupies a practical midpoint — offering dosing flexibility for both conservative and experienced protocols without the volumetric overcorrection of ultra-high-concentration presentations. HPLC potency verification and LAL endotoxin screening are applied at the finished-product batch stage, with GMP-aligned filling conducted under laminar-flow enclosures.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Produces lean, nitrogen-retained muscle mass without significant estrogenic fluid accumulation
Stimulates renal erythropoietin output, raising red blood cell count and elevating aerobic work capacity
Aromatises at approximately half the rate of testosterone, confirmed by in-vitro aromatase assay data
Long undecylenate ester maintains stable free-boldenone plasma levels between weekly injections
250mg/ml concentration enables precise dose scaling — from 250mg (1ml) to 500mg (2ml) — without fractional draw ambiguity
GMP-compliant aseptic filling with HPLC concentration verification and LAL endotoxin screening at batch release
10ml multi-dose vial supports full extended-cycle supply from a single sealed container

Phase	Weekly Dose	Volume at 250mg/ml	notes	Note
Introductory / Advantage Assessment	250–300mg	1.0–1.2ml/week	—	Establishes baseline lean-mass and haematocrit response; obtain pre-cycle bloods for comparison
Main Advantage-Optimisation Block	400–500mg	1.6–2.0ml/week	—	Peak zone for combined lean-mass accrual and erythropoietic benefit; split across two injections
Step-Down / Transition Out	200–250mg	0.8–1.0ml/week	Dose ranges are angle-specific (advantages/USP focus). Individual response, haematocrit readings at week 6–8, and stacking context should guide adjustments. This table does not constitute medical advice.	Gradual dose reduction preserves haematocrit and hormonal stability before PCT window

Key takeaways

Expect lower estrogenic side effects compared to testosterone at equivalent doses.
Leverage erythropoietic stimulation to improve training-session aerobic capacity.
Confirm batch HPLC potency data before committing to a multi-week protocol.
Use the 250mg/ml concentration for flexible weekly dosing without volumetric error.
Store opened vials at 15–25°C and discard on any visible discolouration.

What Makes Boldenone Undecylenate a Distinct Anabolic Choice

Swiss Pharma Boldenone 250mg/ml is defined by its compound-level profile of advantages: an anabolic steroid that produces progressive lean tissue gains, meaningful haematopoietic stimulation, and a comparatively low estrogenic burden relative to testosterone at equivalent weekly doses. Those three properties operate simultaneously rather than sequentially, which is the fundamental reason athletes continue selecting boldenone undecylenate over shorter-ester or higher-aromatising alternatives for extended preparatory blocks.

Boldenone undecylenate stimulates renal erythropoietin secretion, increasing circulating red blood cell mass and improving oxygen-carrying capacity during training — a measurable aerobic benefit distinct from the purely contractile gains produced by 17α-alkylated orals. Compared to testosterone enanthate at the same weekly milligram total, boldenone undecylenate aromatises at roughly half the rate as measured in in-vitro aromatase assays, producing lower serum oestradiol and less estrogenic fluid accumulation. Nitrogen retention in skeletal muscle improves under boldenone administration through androgen-receptor-mediated upregulation of anabolic gene expression, providing the biochemical substrate for lean-mass accrual that persists even during moderate caloric restriction.

Unique Selling Points of Swiss Pharma's 250mg/ml Formulation

The 250mg/ml concentration gives users a pragmatic draw volume: a 500mg weekly dose requires exactly 2ml split across two injections, while a 250mg entry-level weekly dose draws only 1ml — both volumes manageable with a standard 3ml syringe without fractional measurement guesswork. Swiss Pharma produces this vial within GMP-compliant aseptic filling lines; each batch undergoes HPLC potency confirmation to verify declared concentration accuracy and a LAL (Limulus Amebocyte Lysate) endotoxin test to confirm injectable-grade sterility before release.

The 10ml multi-dose vial format supports extended protocols of 14–20 weeks from a single sealed unit, eliminating mid-cycle container changes and maintaining septum integrity through bromobutyl rubber closure with verified container-closure integrity at batch release.

Why Users Select Boldenone Undecylenate Over Comparable Anabolics

Athletes prioritise boldenone undecylenate when they require a compound that simultaneously builds lean mass, raises haematocrit, and controls oestrogen-driven side effects — a combination that single-dimension compounds such as pure DHT derivatives or short-ester high-aromatising androgens cannot replicate. The long undecylenate ester provides a steady free-boldenone release that maintains stable plasma concentrations between weekly injections, reducing hormonal variance compared to shorter-ester injectables requiring more frequent administration. Swiss Pharma's formulation delivers this well-established pharmacological profile in a presentation that has been concentration-verified at the finished-product level — not estimated from raw-material intake records alone.

Usage

Establish a full pre-cycle blood panel — including haematocrit, lipid profile, and serum testosterone — to create a personal baseline against which boldenone's advantages can be quantitatively measured.
Draw the required volume using a 3ml syringe for doses above 0.5ml or a 1ml insulin syringe for sub-250mg precision draws; at 250mg/ml each 0.1ml mark on a 3ml syringe equals exactly 25mg.
Administer intramuscularly into a large muscle group (gluteus, vastus lateralis); rotate injection sites across the vial's multi-dose lifespan to prevent localised tissue fatigue.
Maintain a consistent injection-day schedule (e.g., twice weekly) to keep inter-dose plasma fluctuation narrow given the undecylenate ester's hydrolysis timeline.
Re-test haematocrit and key blood markers at the protocol mid-point (typically week 6–8) to confirm that the erythropoietic advantage remains within safe reference ranges (haematocrit below 52% by Coulter counter methodology).
Do not initiate post-cycle therapy immediately after the final injection; allow sufficient plasma clearance time consistent with the long ester length before beginning SERM-based PCT.

Warnings

Contraindications: Not for use in individuals with known hypersensitivity to boldenone or any oil-based injectable excipient. Contraindicated in persons with existing polycythaemia, thromboembolic conditions, prostate carcinoma, or breast carcinoma. Women of childbearing potential should not use this product due to virilisation risk.

Side Effects: Haematocrit elevation is the most compound-specific concern: rising red blood cell mass increases blood viscosity and, at haematocrit values above 52%, raises thromboembolic risk. Androgenic effects — acne, accelerated scalp hair thinning in predisposed individuals — may occur. Estrogenic effects are lower than testosterone but remain possible; AI co-administration should be guided by mid-cycle oestradiol readings rather than prophylactic dosing.

Monitoring: Venous blood panels including haematocrit, haemoglobin, LDL/HDL lipid ratio, and serum testosterone should be obtained before cycle onset, at the mid-point, and post-cycle. Haematocrit reaching 50–52% warrants immediate dose evaluation. Blood donation (where legally and medically permissible) may be considered under physician supervision if haematocrit trends upward.

PCT: Post-cycle therapy should be planned in advance and delayed until adequate plasma clearance has occurred following the last injection, given the ester's extended hydrolysis timeline. Standard SERM protocols (tamoxifen or clomiphene) are appropriate; consult a qualified physician for personalised guidance.

Frequently asked questions

What are the primary performance benefits of boldenone undecylenate compared to testosterone?: Boldenone undecylenate offers three core advantages over testosterone at equivalent weekly doses: approximately half the aromatisation rate (reducing estrogenic side effects), direct erythropoietic stimulation raising red blood cell count and aerobic capacity, and sustained nitrogen retention for lean-mass accrual. These properties make it a preferred choice for athletes who want anabolic output with lower oestrogen-driven fluid accumulation and a cleaner visual outcome.
What unique characteristics distinguish boldenone undecylenate from other injectable anabolics?: Boldenone undecylenate is uniquely positioned by its dual-axis activity: androgen-receptor-mediated muscle protein synthesis combined with renal erythropoietin stimulation for haematocrit elevation. This combination is not replicated by DHT derivatives, which lack meaningful erythropoietic activity, or by nandrolone, which carries greater progestin-receptor affinity. Its 1,4-diene A-ring structure also prevents 5α-reduction to a more androgenic metabolite, limiting scalp and skin androgenic burden.
Why do experienced bodybuilders consistently choose boldenone undecylenate as part of their anabolic stack?: Experienced athletes select boldenone undecylenate because it occupies a pharmacological niche that testosterone and nandrolone do not fully cover: low estrogenic conversion, measurable haematopoietic benefit, and long plasma stability from the undecylenate ester. These properties allow it to serve as a lean-mass anchor in multi-compound protocols without duplicating the role of the testosterone base, adding a distinct physiological contribution rather than redundant androgenic load.
How should Swiss Pharma Boldenone 250mg/ml be drawn and measured using an insulin syringe for lower weekly doses?: For doses below 250mg, a 1ml insulin syringe graduated in 0.01ml increments allows accurate draws: at 250mg/ml, each 0.01ml graduation corresponds to 2.5mg, giving users 2.5mg dose resolution per mark. A 100mg dose requires a 0.40ml draw and a 150mg dose requires a 0.60ml draw — both achievable without fractional estimation error on a standard insulin syringe.
What are the storage requirements for Swiss Pharma Boldenone 250mg/ml after the vial has been opened?: Once punctured, the 10ml vial should be stored at room temperature between 15°C and 25°C, away from direct light and moisture. Refrigeration is not required but is acceptable; however, cold oil-based solutions should be warmed to room temperature before injection to reduce injection-site discomfort. The benzyl alcohol preservative system in oil-based injectables maintains antimicrobial protection across multiple draws, but the vial should be discarded if visible particulate matter or discolouration develops. (2) angle_used

Manufacturer

Swiss Pharma entered the European pharmaceutical-grade anabolic market with a documented-quality mandate as its founding commercial differentiator — positioning batch-level analytical data (HPLC potency chromatograms, LAL endotoxin records) as public-facing proof of integrity rather than internal compliance artefacts. The brand's manufacturing philosophy centres on aseptic production inside ISO 5 laminar-flow enclosures set within ISO 7 background cleanroom environments, with continuous viable and non-viable particle monitoring logged throughout each production run. Boldenone 250mg/ml is produced within this infrastructure: the benzyl alcohol and benzyl benzoate carrier system is selected for its established antimicrobial preservative profile in oil-based multi-dose vials, and container-closure integrity is verified at batch release alongside the HPLC and endotoxin records. Swiss Pharma's 10ml vial format for Boldenone 250mg/ml reflects a deliberate specification choice: a single sealed unit supplies the compound quantity required for a complete extended protocol without mid-cycle container changes, while the bromobutyl rubber septum maintains low-extractable compatibility with the oil-based matrix across the full multi-dose service life of the vial.

Product details

Brand	Swiss Pharma
Active ingredient	boldenone undecylenate
Also known as	Equipoise, EQ, Boldenone Undecylenate, Boldenonee, Swiss Pharma Equipoise
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-BOLD-SWI-250-024

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00

Stack it with

Pairs well with these products.

High Concentration